3Wk·

Gilead drug effectively protects against HIV infection $GILD (-0.23%)


A six-monthly vaccination with the drug lenacapavir effectively protects against HIV infection.


This is confirmed by data from the pivotal Phase 3 study "Purpose 2", which is presented in the "New England Journal of Medicine" ("NEJM"). Astrid Berner-Rodoreda from Heidelberg University Hospital praised lenacapavir as a real breakthrough.


As a depot injection, lenacapavir provides long-term protection against HIV infection, with a booster scheduled every six months - previously used drugs for HIV pre-exposure prophylaxis (PrEP) such as Truvada must be taken daily as a tablet. Getting vaccinated twice a year is much more convenient than having to remember to take a tablet every day, said Berner-Rodoreda.


https://www.finanzen.net/nachricht/aktien/studie-gilead-aktie-steigt-gilead-wirkstoff-schuetzt-effektiv-vor-hiv-infektion-14054625

28.11
Gilead Sciences logo
Bought x20 at €90.29
€1,805.80
previw image
12
11 Comments

profile image
super buy my friend
View all 4 further answers
profile image
Thanks for the info. I heard it on the radio today and didn't remember the name of the company. Keep your fingers crossed for your investment.😊🚀
Show answer
profile image
Have you read up on who the stuff is actually intended for and who the most important target groups of "prep" are?
View all 3 further answers
Join the conversation